Retagliptin (SP2086) 是一种选择性的竞争性，且具有口服活性的二肽基肽酶 4 (DPP-4) 抑制剂。Retagliptin 可用于 2 型糖尿病 (T2DM) 的研究。
货号:ajcx35154
CAS:1174122-54-3
分子式:C19H18F6N4O3
分子量：464.36
溶解度:DMSO : 100 mg/mL (215.35 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research[1].

Retagliptin is a class of compound used for research of type 2 diabetes. Retagliptin inhibits the degradation of GLP-1, thus amplifying the incretin effect[1].

[1]. Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419.